Seres Completes Enrollment for SER-287 Phase 1b Clinical Trial in Patients with UC

Seres Completes Enrollment for SER-287 Phase 1b Clinical Trial in Patients with UC
All patients with mild-to-moderate ulcerative colitis (UC) have been enrolled in Seres Therapeutics‘ ongoing Phase 1b clinical study evaluating the company’s drug therapy candidate, SER-287. The ongoing randomized, placebo-controlled, multiple-dose, Phase 1b study (NCT02618187) is evaluating SER-287 versus a placebo drug in 58 patients with mild-to-moderate UC, who are failing to respond to other therapies, at several

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *